Abstract library

18 results for "costs".
#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database
Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: PhD Delphine Gueguen
#2713 The Economic Impact to Patients with Neuroendocrine Tumours
Introduction: The quality of life impact on patients with neuroendocrine tumours (NETs) and the economic burden on health systems are substantial. However, little is known about the economic burden to individual patients and families for medical out-of-pocket expenses and employment decisions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Assoc Prof David Wyld
Authors: Wyld D, Elliott T, Wakelin K, Leyden S, ...
#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis
Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Marion Feuilly
#209 A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional
Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MSc Anders Öhberg
#442 Low Diagnostic Accuracy of Tumor Markers for the Annual Screening of Pancreatic Neuroendocrine Tumors in MEN-1 Patients
Introduction: The use of tumor markers for annual screening for pancreatic neuroendocrine tumors (pNET) in Multiple Endocrine Neoplasia type 1 (MEN-1) is debatable because of low-level evidence and high costs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD PhD Gerlof Valk
#469 Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors (pNET) that have spread or cannot be removed by surgery.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Mónica Inês
Authors: Soares M, Inês M, Contente M, ...
#514 Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands
Introduction: Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor approved and reimbursed in the Netherlands for use in advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Huib Scheijbeler
#538 Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales
Introduction: SU is an oral multitargeted tyrosine kinase inhibitor approved in Europe for advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Adam Johns
Authors: Johns A, Eatock M, Johal S, ...
#539 Patterns of Care of Neuroendocrine Cancer in Ontario: Health Services Delivery
Introduction: Delayed diagnosis and treatment of NETs may result in increased health care utilization, medical costs and patient distress. Patients may be treated by different specialists and modalities.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Simron Singh
Authors: Singh S, Cukier M, Liu N, Saskin R, ...
#1303 Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals
Introduction: Lanreotide depot (LAN) was recently approved by the FDA to treat mGEP-NETs to improve progression-free survival.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: George Camba
Authors: Ortendahl J, Pulgar S, Cox D, Bentley T, ...